Overview of Nicor

Quick Facts

Property	Description
Active ingredient	Nicorandil (INN)
Forms	Oral Tablet, Intravenous Injection
Pharmacological class	Vasodilator / Antianginal agent
Mechanism principle	Dual action (Nitrate-like + K-channel opener)
Origin	Synthetic (Niacinamide derivative)

What Type of Drug is Nicorandil?

Nicorandil is a unique, synthetic medication classified as an antianginal agent and a dual-action vasodilator. It is primarily used to manage and reduce chest pain (angina) by enhancing the blood and oxygen supply to the heart muscle. The World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) Classification System categorizes Nicorandil under C01DX16 (Other vasodilators used in cardiac diseases).

As the International Nonproprietary Name (INN), Nicorandil is a synthetic compound derived from niacinamide (a form of Vitamin B3) that possesses a nitrate component in its chemical structure. This chemical duality is clinically recognized for providing comprehensive vascular benefits supported by pharmacological studies.

The Dual-Action Difference

The drug is notable for its two distinct mechanisms of action, which work together to relax blood vessels. Nicorandil functions both as a nitric oxide (NO) donor and as an ATP-sensitive potassium channel (KATP channel) opener. This dual mechanism provides both potent coronary vasodilation and cardioprotection. In simpler terms, this medicine works in two ways to widen blood vessels and also helps protect the heart muscle from stress.

This combined approach means the drug helps widen both the large veins and arteries (like a nitrate) and the smaller resistance arteries. This balanced dilation is a key differentiating factor that reduces pressure on the heart while simultaneously improving blood flow directly to the heart muscle.

Form and Composition: What's in Nicorandil?

Nicorandil is typically supplied as a single-active-ingredient formulation for systemic administration. The primary form is an oral tablet intended for regular, long-term use. The drug is also available as an intravenous injection for rapid effect in acute or hospital settings.

The medication contains only the active compound, Nicorandil, alongside standard pharmaceutical excipients. As a nicotinamide derivative, Nicorandil reduces preload and afterload. This means the medicine decreases the overall workload and pressure on the heart by relaxing the blood vessels.

What side effects are possible with Nicor?

Official Side Effects and Safety Characteristics

Nicorandil's safety profile is documented by government regulatory bodies, classifying adverse reactions by frequency and the physiological system affected. The majority of these effects are related to the medicine's vasodilatory action.

Frequency-Classified Adverse Reactions

The following summary of adverse reactions is based on official regulatory classifications:

Very Common (Affects 1 in 10 or more people): Headache.
Common (Affects 1 to 10 in 100 people): Nausea, vomiting, cutaneous vasodilation (flushing), and malaise (feeling of weakness).
Uncommon to Rare (Less frequent): These include mouth ulceration (uncommon), muscle pain (myalgia), rash, and, rarely, angioedema. Abdominal pain and hepatic dysfunction are documented as very rare occurrences.

Serious Adverse Reactions and Safety Constraints

Official labeling documents the risk of ulceration, which is considered a serious adverse reaction. Ulcerations can affect the mouth, gastrointestinal tract, anal region, and other mucosal sites, with potential for complications like perforation or hemorrhage.

Regulatory restrictions state that nicorandil is contraindicated in certain situations, including use with phosphodiesterase-5 (PDE-5) inhibitors (due to the risk of severe blood pressure reduction) and in patients with cardiogenic shock or severe hypotension.

Time-related safety patterns note that the very common headache is typically expected to appear at the start of treatment. Additionally, caution is advised for older adults due to a potentially increased risk of ulcerations, as per regulatory safety documentation.

Overdose and Emergency Response

Nicorandil Overdose and When to Seek Help

Overdosage with Nicorandil is officially documented to result from an exaggeration of its intended vasodilatory effects, primarily affecting the cardiovascular system. This profile is consistent across authoritative regulatory documents.

Manifestations and Outcomes	Officially Documented Information
Documented Signs	Pronounced peripheral vasodilation, a significant fall in blood pressure (hypotension), and reflex tachycardia (increased heart rate) as a compensatory response.
Severe Outcome	Overdosage can lead to a state of severe hypotension, which may progress to a life-threatening situation.
Antidote Status	No specific antidote is known for Nicorandil overdose.

Required Emergency Actions

Immediate medical attention must be sought if signs of severe overdose, particularly profound hypotension or an unstable hemodynamic state, are suspected. The regulatory authorities mandate that emergency management is strictly symptomatic and supportive.

Clinical procedures documented in the prescribing information include the application of general supportive measures and continuous monitoring of cardiac function. A key step in management is to increase the circulating plasma volume via the infusion of suitable fluid. For cases involving severe, life-threatening hypotension, the administration of vasopressors must be considered to stabilize the patient's hemodynamic status. It is further noted in the official labeling that there is no documented experience of massive overdosage in humans.

Therapeutic Uses of Nicor

What Nicorandil Treats: Main Uses and Benefits

Nicorandil is a medication commonly used to help with the symptomatic relief of angina pectoris. It is commonly used in adults for managing symptoms related to stable angina and is considered relevant for easing symptoms related to difficult-to-manage manifestations, such as angina characterized by spontaneous, unpredictable episodes (rest angina). The medication may be part of symptomatic management when symptoms related to physical discomfort create noticeable physiological strain.

A key benefit is that the medication helps address symptom clusters that may become intense or disruptive, such as the recurring pain associated with effort, and may help patients cope more steadily with symptom fluctuations. It is also relevant in contexts involving heightened systemic burden or physical strain during high-risk scenarios. “The treatment supports patients during episodes of heightened discomfort and assists with maintaining functional stability.”

Quick Fact: Relief for Chest Discomfort

Primary Symptom	Therapeutic Benefit	Clinical Scenario
Effort-induced pain	Helps ease the overall symptom load	Chronic stable angina
Spontaneous discomfort	Supports symptom management	Episodic angina patterns
Physiological strain	Supports general well-being	Supportive assistance/PCI context

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Nicorandil — official regulatory information

Nicorandil (often marketed as Nicor or Ikorel) is a prescription medicine indicated for the symptomatic treatment of stable angina pectoris in adults who cannot take or are inadequately controlled by first-line therapies, such as beta-blockers or calcium antagonists.

Eligibility scope

Category	Regulatory Statement
Populations for whom use is contraindicated	Hypersensitivity to the drug or excipients. Patients with shock (including cardiogenic shock), severe hypotension (very low blood pressure), hypovolaemia (low blood volume), or acute pulmonary oedema. Use with phosphodiesterase 5 inhibitors (e.g., sildenafil, tadalafil) or soluble guanylate cyclase stimulators (e.g., riociguat) is strictly prohibited due to risk of a serious blood pressure drop.
Age-related eligibility rules	Paediatric use is not recommended as safety and efficacy have not been established in this patient group. Elderly patients have no special dose requirements but should use the lowest effective dose.
Condition-specific eligibility rules	Caution is advised for patients with Heart Failure Class NYHA III or IV and those with Glucose-6-phosphate dehydrogenase (G6PD) deficiency. Use in patients with diverticular disease requires caution due to an increased risk of perforation or fistula formation. No special dose adjustments are required for liver or renal impairment.
Pregnancy and lactation eligibility status	Avoidance is preferable during pregnancy due to limited human data. Not recommended during breastfeeding as it is unknown if the drug is excreted in human milk.

Connection to the overall eligibility profile

Official regulatory documents define Nicorandil as a second-line treatment strictly for adults with stable angina who meet specific criteria. The eligibility profile is characterized by several absolute contraindications targeting acute circulatory and heart failure states, as well as prohibited drug combinations that cause severe hypotension. Use is formally not recommended for paediatric and breastfeeding populations, classifying it as a restricted-use medicine in these groups due to a lack of safety data.

What should I know about interactions with other medicines?

Nicor Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Nicorandil (Nicor) as stated in government regulatory sources.

Formally Contraindicated Combinations

Certain combinations are prohibited due to the risk of severe blood pressure drops (hypotension). Regulatory documents specify that Nicorandil must not be co-administered with the following drug classes:

Phosphodiesterase 5 (PDE5) Inhibitors (e.g., Sildenafil, Tadalafil, Vardenafil).
Soluble Guanylate Cyclase (sGC) Stimulators (e.g., Riociguat).

Documented Pharmacodynamic and Risk Interactions

Co-administration with other medicines can result in additive effects or specific risk increases, requiring caution as documented in official labeling.

Interacting Product Category	Officially Documented Effect	Constraint Type
Antihypertensive Agents/Other Vasodilators	Increased blood pressure lowering effect (additive hypotension).	Use with Caution
Potassium-Increasing Products (e.g., ACE Inhibitors)	Potential risk of severe hyperkalaemia (high blood potassium levels).	Use with Caution
NSAIDs or Corticosteroids	Increased risk of gastrointestinal ulceration and haemorrhage.	Use with Caution

Pharmacokinetic and Substance Interactions

Studies show that standard metabolic inhibitors (Cimetidine) and inducers (Rifampicin) do not significantly modify Nicorandil’s overall exposure.

Food delays the rate of Nicorandil absorption but does not affect the total amount absorbed. Regulatory documents also note that the possibility of Nicorandil potentiating the effects of alcohol cannot be excluded.

Mechanism of Action

How Nicor Works

Nicorandil's action is defined by a balanced dual mechanism that influences vascular smooth muscle tone and cellular resilience through two distinct molecular pathways. This dual approach modulates both the large vessel system and the microcirculation.

Dual Modulation of Vascular Tone via NO and K ATP

This core mechanism involves the drug acting as both a Nitric Oxide ( NO) donor and an ATP-sensitive potassium ( K ATP) channel opener. The NO component initiates the cGMP signaling cascade, while the K ATP channel opening causes membrane hyperpolarization through potassium ion ( K^+) efflux. These parallel actions cause widespread vascular smooth muscle relaxation which, at a systemic level, reduces ventricular filling pressure (preload) and decreases systemic vascular resistance (afterload).

Selective Modulation of Coronary Blood Supply

The K ATP channel opening mechanism produces a distinct physiological effect by causing the selective relaxation and dilation of coronary resistance arteries. This direct action increases blood flow and oxygen supply to the heart muscle tissue. The K ATP component supports sustained vascular responsiveness, a mechanism that does not exhibit the same diminished activity pattern as the NO donation pathway.

Dosage and Administration Information

How Nicorandil is Used: Official Administration Guidelines

Nicorandil is used via the oral route as a tablet for the long-term management of chronic stable angina. The usage protocol is defined to ensure consistent and appropriate administration.

Standard Dosing Regimens

Treatment begins with a low starting dose, which is then adjusted, or titrated, based on the patient's individual needs and tolerance, as outlined in the prescribing information.

Dosing Parameter	Official Instruction (Oral Tablet)
Usual Starting Dose	10 mg twice daily (bid)
Alternative Starting Dose	5 mg twice daily (May be used for patients prone to headache)
Maximum Recommended Dose	Up to 40 mg twice daily

Frequency and Conditions of Intake

Nicorandil tablets are administered twice daily, preferably in the morning and evening, for continued symptom management.

Condition	Official Instruction
Intake Method	Tablets must be swallowed whole with some liquid.
Food Relationship	Administration is independent of food intake (may be taken with or without food).
Preparation	Tablets may be divided to facilitate the lower starting dose.

Population-Specific Guidance

Official instructions provide guidance for specific patient populations:

Older Adults: While no special dose is required, use of the lowest effective dose is recommended.
Pediatric Population: Nicorandil is not recommended for use in individuals under 18 years of age.

To maintain the quality of the medicine, tablets are sensitive to moisture and should be kept in their original packaging until intake.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nicorandil

Evidence for Managing Long-Term Angina Symptoms

Research into the long-term use of Nicorandil was studied for outcomes related to physical discomfort in patients with stable angina. This evidence is primarily derived from large, international Randomized Controlled Trials (RCTs) and ongoing Observational Studies. These studies focused on adults diagnosed with stable angina pectorus, often evaluating the medicine when it was administered in addition to other established therapies.

Researchers monitored major cardiovascular outcomes over an extended time, including hospitalization for cardiac chest pain and the occurrence of major heart events. In studies spanning an average of \approx1.6 years, data show patterns related to these combined outcomes in the study populations. Findings help contextualize how patients reported their experience, monitoring changes in outcomes related to physical discomfort over defined time intervals.

Evidence for Heart Protection During Acute Procedures (PCI)

Nicorandil was studied for its potential role in acute care settings, specifically in patients undergoing Percutaneous Coronary Intervention (PCI). The primary research focus was evaluated in the acute hospital setting, specifically periprocedural myocardial injury (PMI).

Studies utilized the injection form and explored outcomes related to systemic or functional imbalance, such as microvascular function (blood flow in the smallest heart vessels) and the incidence of the "no-reflow" phenomenon. Findings describe patterns observed in the studies related to the measurement of myocardial injury and monitoring of some indicators of blood flow after the intervention.

Findings were mixed across some studies, particularly concerning Major Adverse Cardiovascular Events (MACE) over the intermediate term, and variability exists in the research based on the specific delivery methods used.

Unanswered Questions and Research Gaps

Despite the existing research, several aspects remain uncertain. The comparative evidence is lacking between Nicorandil and all other available anti-anginal medications in contemporary, head-to-head randomized trials. Furthermore, outcomes based on secondary or smaller studies, such as potential kidney protection, mean that the certainty remains low until larger, dedicated research can provide clearer context. There is limited information for long-term outcomes beyond a few years in many contemporary studies.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Nicor (FAQ)

Q: How quickly should Nicor start working after I begin taking it?

A: Official information indicates that the concentration of the medicine in the blood reaches its peak about 30–60 minutes after taking a single tablet. Full symptomatic management may typically take approximately four to five days of consistent use to be established, according to clinical data.

Q: How long does the effect of a single Nicor dose typically last?

A: While the medicine's half-life (the time it takes for half the drug to leave the body) is about one hour, the documented anti-angina effects can last longer. Studies and official documents indicate that the effect of Nicorandil against symptoms is generally reported to last for up to 8 to 12 hours.

Q: Does Nicor cause fatigue or changes in energy levels?

A: Official information derived from clinical reports lists feeling weak and lethargy (a lack of energy or enthusiasm) as common side effects that have been associated with the use of this medicine.

Q: What are the most commonly reported side effects of Nicor?

A: According to official product information, the most frequently reported side effects are generally mild and include headache, dizziness, flushing (redness of the face and neck), nausea, and vomiting.

Q: Does Nicor interact with common over-the-counter pain relievers?

A: Regulatory documents indicate that the use of certain pain relievers, specifically Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), is associated with an increased risk of stomach ulceration when combined with this medicine. Official sources do not list the same increased risk of ulceration when Nicorandil is used with paracetamol.

Q: Can I take vitamins or supplements while using Nicor?

A: Official product information notes specific caution is needed if taking products that may increase potassium levels, such as potassium supplements. Regulatory documents advise informing a healthcare professional about all supplements and herbal remedies being used.

Q: Can I take Nicor if I have kidney issues?

A: Official information notes that having pre-existing kidney problems is a factor that should be discussed with a healthcare professional before starting this medicine.

Q: Are there any specific warnings about Nicor for people with liver problems?

A: Reports indicate that liver dysfunction, such as hepatitis or jaundice, has been noted as a very rare side effect in association with Nicorandil use. Furthermore, regulatory documents suggest the drug's action is not significantly impacted by certain medicines that affect liver processing.

Q: Can Nicor interact with antidepressant medications?

A: Yes, official regulatory sources report that Nicorandil may potentiate the blood pressure-lowering effect when used alongside certain medications. This is specifically noted for certain types of antidepressants, such as tricyclic antidepressants.

Q: Is it true that Nicor can cause weight changes?

A: Official reporting lists weight loss in association with cases of gastrointestinal ulcerations, which are considered a rare but serious adverse event of the medicine. This is the primary context in which weight change is noted in association with Nicorandil in official regulatory documents.

Q: Can Nicor affect my ability to drive or operate machinery?

A: Because Nicorandil can cause side effects like dizziness or lightheadedness, regulatory information advises caution. Official advice notes that patients should determine if their ability to perform these tasks is unimpaired before driving or operating machinery.

Q: Are there any specific foods or drinks to avoid when taking Nicor?

A: Regulatory warnings indicate that alcohol consumption should be avoided or limited. This is because alcohol may increase the blood pressure-lowering effects of the medicine, which could increase feelings of dizziness or weakness.

Q: Why do some people report feeling anxious when starting Nicor?

A: Official drug labels, which list potential adverse reactions reported by patients in studies, include nervousness as a potential side effect that may be experienced by some individuals.

Q: Can Nicor affect my sleep?

A: Official product information lists insomnia (difficulty falling or staying asleep) and trouble sleeping as reported side effects of the medicine.

Q: What research evidence supports the use of Nicor?

A: Evidence supporting the use of this medicine for chronic stable angina is based on various clinical trials and research. Research includes large-scale outcome studies, such as the IONA trial, which examined the effects of the medicine on patient outcomes.

Q: Can women who are planning pregnancy use Nicor?

A: The use of this medicine is generally avoided during pregnancy as a standard precautionary measure. Official documents advise consulting a healthcare professional if a woman is pregnant, planning a baby, or breastfeeding.

Q: Is it normal to feel no immediate change when starting Nicor?

A: While the medicine does start working within an hour, clinical and regulatory information suggests this is a normal expectation, as the full, continuous therapeutic effect for chronic symptom management can take around four to five days to be fully established.

Q: Are there published studies about the long-term safety profile of Nicor?

A: Yes, long-term clinical data is available and has been used to assess the safety of the medicine. Studies like the IONA trial have examined the effects of Nicorandil on patient outcomes and safety over extended periods of time.

Q: Can Nicor interact with heart rhythm medications?

A: Official sources have investigated the use of this medicine alongside common heart rhythm drugs. Studies have not found specific pharmacokinetic or pharmacological interactions with certain anti-arrhythmic agents, such as beta-blockers and digoxin.

Q: Is Nicor known to cause any skin reactions or rashes?

A: Official reporting lists rash as an uncommon side effect of the medicine. Furthermore, in rare instances, reports of severe effects such as skin ulcers have been noted in official drug information.

Q: Do official sources discuss discontinuing Nicor?

A: Official documents describe that treatment for chronic angina is usually long-term. However, they indicate that treatment may be considered for discontinuation if a patient experiences persistent or severe adverse effects, such as ulcers.

Q: Is Nicor only used for a specific type of the condition it treats?

A: Yes, regulatory authorities have officially approved and indicated the medicine for the symptomatic treatment of chronic stable angina pectoris. This is the specific type of chest pain for which it is prescribed.

Q: Is Nicor associated with any changes in mood or behavior?

A: Official drug labels list certain mood-related effects as potential side effects. These include reports of depression and nervousness.

Q: What evidence themes are consistently highlighted in Nicor's clinical research?

A: Research and clinical literature consistently focus on the drug's dual mechanism of action, which involves its activity as an ATP-sensitive potassium channel activator. Another key theme is the study of its potential cardioprotective effects in patients with coronary artery disease.

How should Nicor be stored and disposed of?

The storage and disposal of Nicorandil tablets are governed by strict regulatory requirements focused on preserving the medicine’s quality and stability.

Storage Conditions

Nicorandil must be stored below 25°C and must be protected from moisture. Due to the tablet's sensitivity to humidity, it is mandatory to keep the medicine in the original package and to leave tablets in their blister until intake. Once a blister strip is opened, the tablets on that strip have a limited period of use and must be used within 30 days of opening.

Disposal and Safety

For safety, the medication must be stored out of the sight and reach of children.

Any unused or expired Nicorandil product must be disposed of in accordance with local requirements for pharmaceutical waste.

Nicor